Adaptimmune Therapeutics plc (NASDAQ:ADAP) Receives Consensus Rating of 'Moderate Buy'

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has achieved a consensus rating of "Moderate Buy" from five brokerages that currently cover the stock, according to Marketbeat.com. Among these analysts, one has issued a hold recommendation, while four have given a buy recommendation for the company. The average price target over the next twelve months from these brokerages is set at $2.18.

Multiple research analysts have provided insights on Adaptimmune's stock. Mizuho has recently lowered its price target from $3.00 to $1.50 while maintaining an "outperform" rating. In a similar vein, Wells Fargo decreased their price objective from $2.00 to $1.50 and assigned an "equal weight" rating. Additionally, Scotiabank cut their target price from $3.15 to $1.40, opting for a "sector outperform" rating.

Recent Trading Activity

On Friday, trading for NASDAQ ADAP saw an increase of 3.9%, reaching $0.29. Over 4,999,050 shares were traded, significantly higher than the average volume of 1,407,286 shares. Overall, the company's market capitalization stands at $74.41 million, with a PE ratio of -1.32 and a beta measure of 2.52. Current liquidity ratios are quite healthy, with a quick ratio of 3.82 and a current ratio of 3.85. The stock exhibits a debt-to-equity ratio of 0.62 and has recorded a 50-day moving average of $0.55 and a 200-day moving average of $0.71. Adaptimmune's shares have fluctuated between a 52-week low of $0.26 and a high of $1.65.

Institutional Investors' Perspectives

Several institutional investors have altered their positions in Adaptimmune recently. Invesco Ltd. increased its stake by 82.0% during the last quarter, now owning 63,335 shares valued at $34,000. Two Sigma Advisers LP amplified their stake by an impressive 492.0%, holding now 70,735 shares worth $38,000. Meanwhile, Virtu Financial LLC also raised its holdings by 21.5%, now managing 122,696 shares valued at $66,000. Hedge funds and institutional investors collectively own 31.37% of the stock.

Company Overview

Adaptimmune Therapeutics plc is a biopharmaceutical company currently in clinical stages, focusing on innovative cell therapies primarily for cancer patients in the U.S. and the U.K. Their notable ongoing studies include SPEARHEAD-1, which is in phase II trials with ADP-A2M4 for synovial sarcoma, SURPASS-3 in phase II trials for patients with platinum-resistant ovarian cancer, and several phase I trials under the SURPASS label targeting head, neck, and urothelial cancers.

Adaptimmune, Therapeutics, Analysts